KeyCorp Lowers Tenet Healthcare (NYSE:THC) Price Target to $225.00

Tenet Healthcare (NYSE:THC) had its target price reduced by equities research analysts at KeyCorp from $250.00 to $225.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. KeyCorp’s price target would suggest a potential upside of 20.61% from the company’s previous close.

THC has been the topic of several other reports. Guggenheim increased their price target on Tenet Healthcare from $271.00 to $283.00 and gave the company a “buy” rating in a report on Thursday, March 12th. Royal Bank Of Canada increased their price target on Tenet Healthcare from $253.00 to $277.00 and gave the company an “outperform” rating in a report on Thursday, February 12th. Jefferies Financial Group increased their price target on Tenet Healthcare from $250.00 to $265.00 and gave the company a “buy” rating in a report on Thursday, February 12th. Wall Street Zen cut Tenet Healthcare from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 25th. Finally, Leerink Partners increased their price target on Tenet Healthcare from $255.00 to $264.00 and gave the company an “outperform” rating in a report on Friday, February 20th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Tenet Healthcare has an average rating of “Moderate Buy” and a consensus price target of $249.17.

Tenet Healthcare Stock Up 5.3%

THC stock traded up $9.44 during midday trading on Friday, hitting $186.56. The company’s stock had a trading volume of 108,548 shares, compared to its average volume of 1,119,912. The company has a market cap of $16.34 billion, a PE ratio of 12.07, a P/E/G ratio of 1.35 and a beta of 1.49. Tenet Healthcare has a 12 month low of $145.27 and a 12 month high of $247.21. The company has a current ratio of 1.76, a quick ratio of 1.68 and a debt-to-equity ratio of 2.18. The firm’s 50-day moving average is $207.31 and its 200-day moving average is $204.17.

Tenet Healthcare (NYSE:THC) last released its quarterly earnings data on Thursday, April 30th. The company reported $4.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.21 by $0.61. The business had revenue of $5.37 billion for the quarter, compared to analysts’ expectations of $5.39 billion. Tenet Healthcare had a return on equity of 26.33% and a net margin of 6.60%.The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the firm posted $4.36 EPS. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. On average, equities research analysts forecast that Tenet Healthcare will post 17.31 earnings per share for the current fiscal year.

Insider Transactions at Tenet Healthcare

In other news, EVP Paola M. Arbour sold 6,500 shares of the company’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $238.43, for a total value of $1,549,795.00. Following the completion of the sale, the executive vice president directly owned 29,291 shares in the company, valued at $6,983,853.13. This represents a 18.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Thomas W. Arnst sold 8,000 shares of the company’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $238.85, for a total value of $1,910,800.00. Following the completion of the sale, the executive vice president owned 12 shares of the company’s stock, valued at $2,866.20. This trade represents a 99.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 46,517 shares of company stock worth $10,943,111 in the last three months. Corporate insiders own 0.81% of the company’s stock.

Institutional Investors Weigh In On Tenet Healthcare

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Wedmont Private Capital raised its holdings in Tenet Healthcare by 2.5% during the fourth quarter. Wedmont Private Capital now owns 2,088 shares of the company’s stock valued at $422,000 after acquiring an additional 50 shares during the period. Baron Wealth Management LLC raised its holdings in Tenet Healthcare by 4.8% during the fourth quarter. Baron Wealth Management LLC now owns 1,142 shares of the company’s stock valued at $227,000 after acquiring an additional 52 shares during the period. Sagespring Wealth Partners LLC grew its position in shares of Tenet Healthcare by 3.6% during the fourth quarter. Sagespring Wealth Partners LLC now owns 1,573 shares of the company’s stock valued at $313,000 after purchasing an additional 55 shares in the last quarter. Quadrant Capital Group LLC grew its position in shares of Tenet Healthcare by 0.7% during the fourth quarter. Quadrant Capital Group LLC now owns 8,134 shares of the company’s stock valued at $1,616,000 after purchasing an additional 58 shares in the last quarter. Finally, Syon Capital LLC grew its position in shares of Tenet Healthcare by 5.3% during the fourth quarter. Syon Capital LLC now owns 1,254 shares of the company’s stock valued at $249,000 after purchasing an additional 63 shares in the last quarter. 95.44% of the stock is owned by institutional investors.

Key Stories Impacting Tenet Healthcare

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: Q1 earnings beat consensus — Tenet reported $4.82 EPS vs. ~$4.21 expected, beating estimates and demonstrating solid profitability and margin control. Zacks: Q1 Earnings Top Estimates
• Positive Sentiment: Big push into ASCs — Tenet deployed ~$125M to acquire seven ASCs in Q1, signaling a strategic shift toward higher-margin outpatient care that should support long-term revenue mix improvement and margin expansion. Becker’s ASC: $125M on 7 ASC acquisitions
• Positive Sentiment: ASC acuity and service expansion — Tenet is seeing double-digit joint replacement growth and runs 150+ robotic surgery programs, which supports higher-acuity outpatient volume and revenue per case over time. Becker’s ASC: ASC acuity push paying off
• Positive Sentiment: Management execution praised — Management attributed navigating Q1 volume variability to disciplined operations, which investors view as supportive of margins and cash flow. FierceHealthcare: Met Q1’s volume curveballs
• Neutral Sentiment: FY‑2026 guidance provided — Tenet issued EPS guidance of roughly $16.38–$18.68 (consensus ~17.22) and revenue guidance centered near consensus, leaving room for interpretation but giving investors forward visibility. Yahoo Finance: Q1 2026 Earnings Call Summary
• Negative Sentiment: Revenue slight miss and admissions/payer-mix headwinds — Revenue came in a touch below estimates (~$5.37B vs. $5.39B expected) and management cited an unfavorable admissions mix and external disruptions that weighed on top-line performance. Benzinga: Blames admissions mix for soft Q1 sales

Tenet Healthcare Company Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.